NCT01687283 - Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma | Biotech Hunter

Enrollment

316

Participants

Timeline

Start Date

September 27, 2012

Primary Completion Date

November 7, 2013

Study Completion Date

November 7, 2013

Conditions

Asthma

Interventions

DRUG

fluticasone propionate inhalation solution

1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID

DRUG

budesonide suspension

2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID

Trial Locations (25)

100029

GSK Investigational Site, Beijing

100088

GSK Investigational Site, Beijing

110001

GSK Investigational Site, Shenyang

110015

GSK Investigational Site, Shenyang

200025

GSK Investigational Site, Shanghai

200072

GSK Investigational Site, Shanghai

214023

GSK Investigational Site, Wuxi

221006

GSK Investigational Site, Xuzhou

250012

GSK Investigational Site, Jinan

250013

GSK Investigational Site, Jinan

266071

GSK Investigational Site, Qingdao

310016

GSK Investigational Site, Hangzhou

330006

GSK Investigational Site, Nanchang

400038

GSK Investigational Site, Chongqing

410004

GSK Investigational Site, Changsha

410011

GSK Investigational Site, Changsha

510080

GSK Investigational Site, Guangzhou

510180

GSK Investigational Site, Guangzhou

524001

GSK Investigational Site, Zhanjiang

610041

GSK Investigational Site, Chengdu

610072

GSK Investigational Site, Chengdu

750004

GSK Investigational Site, Yinchuan

Unknown

GSK Investigational Site, Taiyuan

GSK Investigational Site, Hangzhou

GSK Investigational Site, Chongqing